Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 318 for:    colon cancer | ( Map: Canada )

VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00407654
Recruitment Status : Completed
First Posted : December 5, 2006
Results First Posted : August 18, 2015
Last Update Posted : August 24, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE December 4, 2006
First Posted Date  ICMJE December 5, 2006
Results First Submitted Date  ICMJE March 27, 2015
Results First Posted Date  ICMJE August 18, 2015
Last Update Posted Date August 24, 2018
Study Start Date  ICMJE October 2006
Actual Primary Completion Date September 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 22, 2015)
  • Objective Tumor Response (Defined as Partial or Complete Response as Defined by the RECIST Criteria) [ Time Frame: Up to 6 years ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions
  • Progression-free Survival (Bevacizumab- naïve Group) [ Time Frame: 4 months ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used.Progression-free survival (Bevacizumab- naïve group)
  • Progression-free Survival (Bevacizumab-treated Group) [ Time Frame: 4 months ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Kaplan-Meier method will be used. Progression-free survival (Bevacizumab-treated group)
Original Primary Outcome Measures  ICMJE
 (submitted: December 4, 2006)
  • Objective tumor response in terms of partial or complete response
  • Progression-free survival at 4 months
Change History Complete list of historical versions of study NCT00407654 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 22, 2015)
  • Overall Survival (Bevacizumab-naïve Group) [ Time Frame: 12 months ]
    Kaplan-Meier method will be used. (Bevacizumab- naïve Group)
  • Overall Survival (Prior Bevacizumab Treated Group) [ Time Frame: 12 months ]
    Kaplan-Meier method will be used (Bevacizumab-naïve Group)
  • Time to Progression [ Time Frame: 12 months ]
    Kaplan-Meier method will be used.
  • Objective Stable Disease Rate [ Time Frame: Up to 6 years ]
  • Number of Participants With Response (Bevacizumab-naïve Group) [ Time Frame: Up to 6 years ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks
  • Overall Survival (Bevacizumab-treated Group) [ Time Frame: 6 months ]
    Kaplan-Meier method will be used. (Bevacizumab-treated Group)
  • Overall Survival (Bevacizumab-treated Group) [ Time Frame: 12 months ]
    Kaplan-Meier method will be used (Bevacizumab-treated Group)
  • Number of Participants With Response (Bevacizumab-treated Group) [ Time Frame: Up to 6 years ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions; Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Stable disease for atleast 16 weeks
Original Secondary Outcome Measures  ICMJE
 (submitted: December 4, 2006)
  • Overall survival (median, 6-month, 1-year)
  • Time to progression (median, 6-month, 1-year)
  • Objective Stable Disease Rate
  • Response duration
  • Toxicity
  • Analysis of laboratory correlates
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Official Title  ICMJE Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Brief Summary This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.
Detailed Description

PRIMARY OBJECTIVES:

I. Determine the response rate (complete and partial) in patients with previously treated metastatic colorectal cancer treated with VEGF Trap.

II. Determine the incidence of disease stabilization, in terms of 4-month progression-free survival, in patients treated with this drug.

SECONDARY OBJECTIVES:

I. Determine the median survival time of patients treated with this drug. II. Determine the 1-year survival rate and stable disease rate in patients treated with this drug.

III. Determine the response or stable disease duration in patients treated with this drug.

IV. Determine the toxicity of this drug in these patients. V. Determine the time to disease progression in patients treated with this drug.

VI. Determine if changes in free VEGF Trap levels correlate with response or toxicity.

OUTLINE: This is a multicenter, open-label study.

Patients are stratified according to prior bevacizumab treatment (yes vs no). Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at the beginning of each course and at 60 days after completion of study treatment. Samples are analyzed by immunoenzyme techniques to determine the pharmacokinetics of VEGF Trap.

After completion of study treatment, patients are followed at 30 and 60 days and then every 3 months thereafter.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Recurrent Colon Cancer
  • Recurrent Rectal Cancer
  • Stage IV Colon Cancer
  • Stage IV Rectal Cancer
Intervention  ICMJE Drug: aflibercept
Given intravenously
Other Names:
  • vascular endothelial growth factor trap
  • VEGF Trap
  • Zaltrap
  • ziv-aflibercept
Study Arms  ICMJE Experimental: Arm I
Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
Intervention: Drug: aflibercept
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 22, 2015)
75
Original Enrollment  ICMJE
 (submitted: December 4, 2006)
80
Actual Study Completion Date  ICMJE September 2012
Actual Primary Completion Date September 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • histologically/cytologically confirmed metastatic colorectal metastatic cancer
  • measurable disease (at least 1 lesion accurately measured in at least 1 dimension (longest diameter) as>20mm with conventional techniques or as >10mm with spiral CT scan
  • >=4 weeks from major surgery
  • at least 1prior line of systemic therapy for metastatic disease. Prior treatment with anti-epidermal growth factor receptor inhibitors is allowed. Last dose >=4 weeks prior to randomization
  • Two cohorts: 1) bevacizumab naïveand; 2) bevacizumab treated
  • May have received prior thymidylate synthetase inhibitor concurrently with radiation as "radiation sensitizer". Last dose >=4 weeks prior to randomization
  • Prior radiation treatment >=4 weeks prior to randomization
  • Age>=18 years
  • Life expectancy >=3 months
  • ECOG<=2 (Karnofsky=60%)
  • leukocytes >3.0x10^9/L
  • absolute neutrophil count >1.5 x 10^9/L
  • platelets>75x10^9/L
  • INR <1.5 unless on warfarin
  • total bilirubin within 1.5xULN
  • AST/ALT≤2.5 X institution ULN
  • creatinine≤1.5xULN OR creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above1.5x institution limits
  • Urinalysis negative for protein OR 24h urine for protein <500 mg
  • full-dose anticoagulants with PT INR >1.5 eligible provided that: a) patient is therapeutic on stable dose of warfarin or low molecular weight heparin; b) patients on warfarin, the upper target for INR is <=3; c) no active bleeding/pathological condition carrying high bleeding risk
  • Eligibility of patients receiving medications known to affect activity/PK of VEGF Trap will be determined by PI
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after completion of VEGF Trap therapy
  • Ability to understand/willingness to sign written informed consent

Exclusion Criteria:

  • chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry
  • Other investigational agents concurrently
  • History of prior anti-angiogenic therapy other than bevacizumab
  • Evidence of CNS disease
  • Known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical/biologic composition to other agents used in the study.
  • Serious/non-healing wound/ulcer/bone fracture
  • History of abdominal fistula/GI perforation/bowel obstruction/intraabdominal abscess within 28 days of treatment
  • major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy
  • anticipation of need for major surgical procedures during study
  • core biopsy within 7 days prior to Day 1 therapy
  • Patients with clinically significant cardiovascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • PT INR >1.5 unless the patient is on full-dose warfarin
  • Use of thrombolytic agents within 1 month of study initiation
  • Significant Proteinuria (>500mg/24h): Urine protein should be screened by random urinalysis for protein. If dipstick positive (>1+), 24-hour urine protein should be obtained and if >500mg/24 h, patient will be excluded.
  • Uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study
  • Pregnant women
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of potential for PK interactions with VEGF Trap
Sex/Gender  ICMJE Not Provided
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00407654
Other Study ID Numbers  ICMJE NCI-2009-00176
PHL-050 ( Other Grant/Funding Number: N01CM62203 )
CDR0000518293 ( Other Grant/Funding Number: N01CM62203 )
N01CM62203 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Cancer Institute (NCI)
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Malcolm Moore University Health Network-Princess Margaret Hospital
PRS Account National Cancer Institute (NCI)
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP